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Bone metastases are common in patients with non–small
cell lung cancer (NSCLC), often causing pain and a decrease
in quality of life (QoL). The effect of bone-targeted agents is
evaluated by reduction in skeletal-related events in which
neither pain nor QoL are included. Radioisotopes can be
administered for more diffuse bone pain that is not eligible
for palliative radiotherapy. The evidence that bone-targeted
agents relieve pain or improve QoL is not solid. We per-
formed a systematic review of the effect of bone-targeted
agents on pain and QoL in patients with NSCLC. Our
systematic literature search included original articles or
abstracts reporting on bisphosphonates, denosumab, or
radioisotopes or combinations thereof in patients with bone
metastases (5 patients with NSCLC), with pain, QoL, or
both serving as the primary or secondary end point. Of the
twenty-ﬁve eligible studies, 13 examined bisphosphonates
(one also examined denosumab) and 12 dealt with radio-
isotopes. None of the randomized studies on bisphospho-
nates or denosumab evaluated pain and QoL as the primary
end point. In the single-arm studies of bisphosphonates a
decrease in pain or analgesic consumption was found
for 38% to 77% of patients. QoL was included in ﬁve of
13 studies, but improvement was found in only two. No
high-level evidence that bisphosphonates or denosumab
reduce pain or improve QoL was found. Although the data
are limited, radioisotopes seem to reduce pain with a rapid
onset of action and duration of response of 1 to 3 months.
The evidence that bisphosphonates or denosumab reduce
or prevent pain in patients with NSCLC and bone metasta-
ses or that they have an inﬂuence on QoL is very weak.
Radioisotopes can be used to reduce diffuse pain, although
there is no high-level evidence supporting such use. 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: Non–small cell lung cancer; Bone metastases;
Bone-targeted agents; Pain; Quality of life
Introduction
Bone metastases develop in approximately 30% to
40% of patients with non–small cell lung cancer (NSCLC)
during the course of their disease, and in more than 60%
of such patients skeletal lesions are found at primary
diagnosis.1–3 To prevent or delay the occurrence of
skeletal-related events (SREs), zoledronic acid, denosu-
mab, or both are usually advised in guidelines. This
advice is based on studies that include not just patients
with NSCLC.4–7 SREs are deﬁned as occult or symp-
tomatic pathological fractures or both, spinal cordJournal of Thoracic Oncology Vol. 11 No. 2: 155-173
Table 1. Criteria for Inclusion in the Review
Criterion Deﬁnition
Subjects included Human only
Language English, German, or Dutch
Article type Original article or conference
proceeding; reviews excluded
Number of patients 5 patients with NSCLCa
Site of primary tumor NSCLCa
Tumor stage IV, with bone metastases
Age 18 y
Treatment Zoledronic acid, denosumab,
radioisotopes, or some
combination thereof; alone or
combined with other treatments
(e.g., chemotherapy)
Follow-up period No lower or upper limit
Dosing, route, and frequency
or duration of treatment
No restrictions
156 Hendriks et al Journal of Thoracic Oncology Vol. 11 No. 2compression, palliative radiotherapy, and sometimes
also hypercalcemia of malignancy (HCM). This composite
measurement was developed for and used as the pri-
mary end point in studies evaluating pharmacological
therapies aimed at bone metastases.8–10 Pain and quality
of life (QoL) are not included in the deﬁnition of SRE.
Bone pain is known to be an important issue in patients
with NSCLC inasmuch as approximately 70% of patients
with the disease require opioids and their pain often
results in a decrease in QoL.11,12 In a Cochrane review
(2002) it was concluded that “there is evidence to sup-
port the effectiveness of bisphosphonates in providing
some pain relief for bone metastases, but there is no
sufﬁcient evidence for effectiveness in different primary
neoplasms.” The review included only one lung cancer
study, and it was published in Chinese only.13 Since then,
reviews have focused mainly on breast and prostate
cancer. In two separate Cochrane systematic reviews,
one on bone metastases in breast cancer and one on
bone metastases in prostate cancer, a signiﬁcant
decrease in pain (breast) and a trend toward a decrease
in pain (prostate) were found.14,15 For lung cancer, not
much data exist. One systematic review (published in
2011 and including only controlled trials) evaluated the
efﬁcacy of bisphosphonates (not restricted to zoledronic
acid) for prevention of SRE, control of pain, and
improvement of overall survival.16 Pain reduction with
zoledronic acid was evaluated in only one study: no
signiﬁcant pain reduction was found when zoledronic
acid was compared with ibandronate.16 In another re-
view (two versions published in 2011, one as a summary
of the other) that included only randomized controlled
trials (RCTs), it was concluded that there are no
adequate RCTs evaluating the effect of bisphosphonates
or denosumab on bone pain and QoL in patients with
NSCLC.17,18 Denosumab was recently registered for the
prevention of SREs in patients with solid tumors and
bone metastases. For pain relief, radioisotopes are
another option.19–22
Although pain and QoL are important issues in
treatment of NSCLC with bone metastases, there are no
RCTs and almost no controlled trials evaluating the ef-
fect of bisphosphonates, denosumab, or radioisotopes on
pain relief and QoL in patients with NSCLC speciﬁcally.
In this systematic review we assess the available evi-
dence on the effect of these agents on bone pain and QoL
in patients with NSCLC.Outcome Pain, QoL, or both as primary or
secondary end point; all methods
for pain measurement or QoL
measurement allowed
aWhen type of “lung cancer” was not speciﬁed as NSCLC or SCLC,
at least ﬁve patients with lung cancer patients had to be included.
NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer;
QoL, quality of life.Methods
Search Strategy and Selection Criteria
A systematic search of the literature published
between 1990 and January 2015 was performed using
the PubMed, Medline, Embase, Web of Science, andCochrane databases. The literature search was per-
formed by following the patient, intervention, compar-
ator, and outcome method,23 which is shown in the
appendix. The search terms were as follows: NSCLC,
non–small cell lung cancer, bone metastases, bone
neoplasm, bisphosphonates, zoledronic acid, radionuclide,
strontium, samarium, rhenium, radioisotopes, radioactive-
labeled bisphosphonates, bone-targeted agents, denosu-
mab, and rank ligand.
Study Selection
After identiﬁcation and exclusion of duplicates, two
authors (L.H. and B.H.) independently screened the titles
and subsequently the abstracts. The same two authors
examined the full texts of selected articles with regard to
the eligibility criteria. The articles reviewed had to
report on bisphosphonates, denosumab, radioisotopes,
or combinations thereof in a population of adults with
cancer in whom bone metastases had been diagnosed;
include at least ﬁve patients with NSCLC; and be written
in English, German, or Dutch. Only original articles and
conference proceedings were included; reviews were
excluded. We chose to include studies irrespective of
their epidemiological design because the reviews of
Lopez-Olivo et al. and Ford et al. made it clear that there
are almost no controlled clinical trials evaluating this
topic that have been written in a language other than
Chinese.16,18 All inclusion and exclusion criteria are
summarized in Table 1. To complete the search and
February 2016 Bisphosphonates, Denosumab, and Radioisotopes in Lung Cancer Patients 157identify all relevant studies, the references of all eligible
articles were manually searched for additional poten-
tially relevant studies.Data Extraction
When available, the following data were extracted
from eligible studies by one researcher (L.H.) and inde-
pendently by another researcher (B.H.): year of publi-
cation; type of study (retrospective or prospective,
phase, number of centers, study duration, and follow-
up); total number of patients included and number of
patients with NSCLC; type of intervention (type, dose,
duration, route, and frequency of administration of
bisphosphonates, denosumab, or radioisotopes or com-
binations thereof); comparator (placebo or another pain
management drug); pain and QoL as primary or sec-
ondary outcomes; method and frequency of measure-
ment of pain and QoL; and results.Records idenﬁed through database
searching
(n=1577)
Titles screened aer removing duplica
(n= 1207)
Abstracts screened
(n=104)
Full text arcles assessed
(n=27)
Included in review
(n=25: 23 arcles and 2 conference
proceedings)
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Figure 1. Flowchart fResults
Selected Articles
The initial search yielded 1577 articles. After removal
of duplicates and screening of titles, 104 abstracts were
identiﬁed. On the basis of those abstracts, 27 articles or
conference proceedings were selected for evaluation on
a full-text basis.
On the basis of the inclusion and exclusion criteria, 18
full publications and two conference proceedings were
deemed eligible for inclusion in this review. A manual
search of the reference lists of the included articles
identiﬁed ﬁve additional relevant articles (see the ﬂow-
chart in Fig. 1).
Study Characteristics
Table 2 (bisphosphonates and denosumab) and
Table 3 (radioisotopes) show the design of the studies
included and summarize the comparison groups within 
tes
 
Duplicates excluded
(Endnote/manually)
(n=370)
Titles excluded
(n=1103) 
Abstracts excluded
(n=77)
Full text arcles excluded with reason
(n=7)
- Duplicate (not clear from abstract)
(n=1)
- No pain and/or QoL data (n=6)
Included aer manual search of 
reference lists of relevant arcles
(n=5)
or article selection.
Table 2. Characteristics of Trials Examining Bisphosphonates and Denosumab
Trial, y Trial Type
Total
Patients/
Patients
with
NSCLC Treatment Arm
Comparator
Arm
Follow-
Up
Primary Study
Objective
Secondary Study
Objectives
Method and Frequency
of Pain Measurement
Bisphosphonates
Piga, 1998 Phase not mentioned,
randomized, double blind,
placebo controlled; number of
centers and time period unclear
50/17 Clodronate, 1600
mg/d orally for 1 y,
chemotherapy when
necessary
Placebo, orally
for 1 y
“at least
3 mo”
Symptom control,
bone metastases;
evolution
measured by
bone scan and
radiograph
None Pain (measured by VAS
scale) and analgesic
consumption, both
monthly
Rosen, 2003;
Update follow-
up: Rosen, 2004
Phase III, randomized, double
blind, placebo controlled,
multicenter; time period
unclear
773/378 CTwith ZOL, 8/4 mg
every 3 wk IV
CTwith placebo
every 3 wk
9-mo
update:
21 mo
Proportion of
patients with
on-study SRE
at 9 mo
Time to on-study SRE,
including HCM; time to
ﬁrst SRE; skeletal
morbidity rate; multiple-
event analysis; pain
score; analgesic use;
ECOG PS; best bone
lesion response; PFS;
bone lesions; OS; bone
markers; QoL
BPI, every 6 wk; analgesic
score every 6 wk; FACT-G,
frequency unclear
Kiaga, 2006 Phase not mentioned,
single arm, single center,
2000–2001
32/32 CTwith IBA, 4 mg by
rapid infusion (20 min)
every 3–4 wk IV until PD
in bone
None Mean 14
mo
Safety and
efﬁcacy
None Changes in analgesic
treatment, every visit
(i.e., every 3–4 wk)
Facchini, 2007 Phase not mentioned,
single arm, single center,
time period unknown
60/28 CTwith ZOL, 4 mg
every 3–4 wk, 12 cycles
None Not
speciﬁed
Pain control,
QoL
Safety, SRE BPI; analgesic
consumption through the
narcotic score; FACT-G,
frequency not mentioned
Kotteas, 2008 Phase not mentioned,
single arm, single center,
2004–2005
86/74
(others
SCLC)
CT with ZOL, 4 mg
every 3–4 wk until
PS deterioration or
unacceptable toxicity
None Mean 18
mo
Safety and
efﬁcacy
None Changes in analgesic
treatment, every visit
(i.e., every 3–4 wk)
Longo (abstract
only), 2008
Retrospective, centers
unclear, 2007–2008
24/18
(others
with SCLC)
CT with ZOL, 4 mg
every 4 wk, cycles
unknown
None Not
speciﬁed
SRE Bone turnover markers,
pain, QoL
BPI, EORTC QLQ-C30,
frequency not mentioned
Zarogoulidis,
2009
Phase not mentioned,
prospective, 2 arms (on basis
of bone pain), number of
centers unknown, years
unknown
144/144 Patients with bone
pain: CT with ZOL,
every 4 wk after
ﬁnishing CT, every
3 wk IV
Patients with
no bone pain:
docetaxel,
100 mg/m2 plus
carboplatin, AUC
6/every 4 wk
(up to 8 cycles)
Unclear OS, PFS, pain None VAS, each clinical visit
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Table 2. Continued
Trial, y Trial Type
Total
Patients/
Patients
with
NSCLC Treatment Arm
Comparator
Arm
Follow-
Up
Primary Study
Objective
Secondary Study
Objectives
Method and Frequency
of Pain Measurement
Francini, 2010 Phase not mentioned,
prospective, randomized,
blinding unknown, centers
unknown, 2005–2010
55/55 CTwith ZOL, 4 mg
every 4 wk IV
CT every 4 wk,
IBA 50, mg/d
orally
3 mo Effect of ZOL/IBA
on bone turnover
markers
Tumor response
(RECIST), pain, SRE
6-Point intensity scale
(McGill-Melzach), at
baseline and at 1 and 3 mo
Ishiwata, 2011 Phase II, 2 arms, (control arm:
patients who refused to enter
study), 2 centers, 2007–2009
35/35 CTwith ZOL,
4 mg IV every
4 wk (4–6 cycles)
Carboplatin
(AUC ¼ 6) every
4 wk with
paclitaxel (70
mg/m2) every
wk or Nedaplatin
(90 mg/m2)
every 4 wk with
paclitaxel (70
mg/m2) every
wk (4–6 cycles)
9 mo Feasibility of
combination of CT
with ZOL
QoL, SRE, toxicity, pain Lung Cancer Symptom
scale, every 4 wk, QOL-
ACD
Del Signore,
2012 (abstract
only)
Retrospective,
centers unknown, 2007–2010
135/135 CTwith ZOL, 4 mg every
4 wk
None Not
speciﬁed
Time to ﬁrst and
second SRE
Pain, QoL VAS each clinical visit,
EORTC QLQ-C30
Yoh, 2012 Phase not mentioned, single
arm, centers unknown,
2007–2009
35/35 CTwith ZOL, 4 mg
every 3–4 wk , 4 cycles,
ZOL continued
afterward until
unacceptable toxicity
None Not
speciﬁed
Feasibility of
combination
of CT with ZOL
Toxicity, SRE, pain
score, best objective
response, OS
BPI baseline and after
6 wk
Davidov, 2013 Phase not mentioned, open
label, single arm, single center,
2004–2008
53/53 ZOL, 4 mg with CT,
(gemcitabine 1250
mg/m2 d1,8 and
cisplatin 80 mg/m2 d1,
every 3–4 wk), number
of cycles not speciﬁed
None Not
speciﬁed
Serum calcium
and AF values
SRE pain “Changes in analgesic
treatment” not otherwise
speciﬁed
Denosumab vs bisphosphonates
Henry, 2014 Phase III, randomized, double
blind, active comparator,
multicenter study, 2006–2009
1597/702 Denosumab, 120
mg SC every 4 wk;
placebo IV every 4 wk
ZOL 4, mg IV
every 4 wk;
placebo SC every
4 wk
7 mo Time to ﬁrst
on-study SRE,
time to ﬁrst and
subsequent SREs
OS, PFS, pain,
analgesic use, AE
11-point BPI-SF, BPI-SF for
pain interference in daily
life, analgesic use: AQA,
frequency: not mentioned
NSCLC, non–small cell lung cancer; VAS, Visual Analogue Scale; CT, chemotherapy; ZOL, zoledronic acid; IV, intravenously; HCM, hypercalcemia of malignancy; BPI, Brief Pain Inventory;
FACT-GT, Functional Assessment of Cancer Therapy-General; IBA, ibandronate; PD, progressive disease; QoL, quality of life; SRE, skeletal-related event; AUC, area under the curve; RECIST,
response evaluation in solid tumors; ECOG, Eastern Cooperative Oncology Group; OS, overall survival; PFS, progression-free survival; AF, alkaline phosphatase; TKI, tyrosine kinase inhibitor;
SCLC, small cell lung cancer; PS, performance score; QOL-ACD, Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs; EORTC QLQ-C30, European Organisation for
Research and Treatment of Cancer Quality-of-Life Questionnaire; SC, subcutaneously; AE, adverse event; BPI-SF, Brief Pain Inventory-Short Form; AQA, analgesic quantiﬁcation algorithm.
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Table 3. Characteristics of the Trials Examining Radioisotopes
Trial, y Trial Type
Total
Patients/
Patients
with NSCLC Treatment Arm
Comparator
Arm
Follow-
Up
Primary Study
Objective
Secondary
Study
Objectives
Method and Frequency of Pain and
QoL Measurement
Farhangi,
1992
Phase I, single arm,
single center, time
period and number
of centers unknown
22/5 Sm-153–EDTMP in
escalating doses, 3.7–37
MBq/kg, single dose IV,
repeated if necessary in
follow-up
None Unclear Pharmacokinetics,
toxicity, pain
response
None VAS 3 times/d
Alberts, 1997 Composite of three
phase I–II trials,
number of centers
unclear, 3-y period,
number of years
unknown
82/9 (“lung
cancer”)
Sm-153–EDTMP, 27.8,
55.5, or 111 MBq/kg IV,
1 dose, when necessary
repeated after 6–8 wk
(up to 4 doses)
None Unclear Efﬁcacy and
toxicity of
different doses
None VAS, frequency not mentioned
Kasalicky,
1998
Prospective, phase
not mentioned,
number of centers
not clear, study
period 3 y, number
of years not clear
118/31 (“lung
cancer”)
89SRCl, 150 MBq single
dose IV, repeated if
necessary in follow-up,
but not within 3 mo
None Unclear Evaluation of
palliative effect,
toxicity
None Analgesic consumption, composite pain
score, improvement in KPS; changes in
mobility, frequency not mentioned
Seraﬁni, 1998 Phase III,
randomized,
double blind,
placebo controlled,
multicenter
1992–1994
118/6 (“lung
cancer”)
A: Sm-153–EDTMP,
18.5 MBq/kg; B:
Sm-153–EDTMP,
37 MBq/kg
Placebob 16 wk Change from baseline
AUC pain and 6-point
pain score at wk 4 as
the primary efﬁcacy
end point
Change in
opioid use
Patient diary:
- Daily VAS for each of 13 body regions
combined into overall pain score
according to methods of Donaldson,
resulting in AUC for consecutive 7-
d periods
- Analgesic consumption, daily
PGA: at every clinical visit (wk
1,2,3,4,8,12,16) 6-point pain score
Tian, 1999 Phase not
mentioned, 2 arm,
randomized,a
single blind
(patient),
multicenter,
start? – 1997
105/41 (“lung
cancer”)
Sm-153–EDTMP,
37 MBq/kg single
dose IV
Sm-153–EDTMP,
18.5 MBq/kg
single dose iv
Unclear Toxicity and pain
reduction
None Patient diary of analgesic consumption,
calculation of “sum of effect product” (on
basis of pain score and time after Sm-153–
EDTMP, the higher the SEP, the better the
effect; weekly for ﬁrst month, every 2 wk
for second month, and every month
thereafter
Küçük, 2000 Phase not
mentioned, single
arm, center and
time not clear
31/5 RE-186–HEDP,
1295 MBq single
dose IV, if necessary
every 3 mo
None Unclear Efﬁcacy and
toxicity
None Surrogate: improvement in ECOG and KPS,
frequency not clear
Li, 2001 Phase II, single arm,
centers and time
period unknown
61/26 (“lung
cancer”)
RE-188–HEDP,
1–4 times IV, mean
dose 1158 MBq
None 1 y Efﬁcacy None 3-point pain scale
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Table 3. Continued
Trial, y Trial Type
Total
Patients/
Patients
with NSCLC Treatment Arm
Comparator
Arm
Follow-
Up
Primary Study
Objective
Secondary
Study
Objectives
Method and Frequency of Pain and
QoL Measurement
Li, 2002 Phase not
mentioned, single
arm, centers and
time period
unknown
66/20 (“lung
cancer”)
Sm-153–EDTMP,
740 MBq single dose IV
None Unclear Relationship between
bone uptake of
Sm-153–EDTMP and
therapeutic effect
None Composite score:
CR: disappearance of >2 bone
metastases, KPS: increase >20, moderate
or complete relief of pain within 7 d of
injection
NR: no disappearance or shrinkage of
metastases, KPS increase <10, no/slight
remission of pain
PR: all other patients
Zhang, 2003 Phase not
mentioned, single
arm, centers and
time period
unknown
30/25 (others
SCLC)
RE-188–HEDP, mean
dose 1158 MBq IV, when
neccessary another dose at
1–1.5 mo
none unclear Efﬁcacy Not
speciﬁed
4-point pain scale weekly, also pain diary
Leondi, 2004 Phase not
mentioned, single
arm, centers and
time period
unknown
24/18 (others
SCLC)
RE-186–HEDP,
1295 MBq iv once
None 8 wk Therapeutic efﬁcacy
RE-186 HEDP
None VAS weekly, evaluation of analgesic
consumption weekly, evaluation of QoL
(surrogate: sleep duration, mobility,
mood, daily activities) weekly
Minutoli, 2006 Phase not
mentioned, single
arm, single center,
time period
unknown
41/17 RE-186–HEDP,
1295 MBq IV, once, another
dose when necessary
None 3 mo Efﬁcacy and toxicity None Pain index based on intensity, frequency,
and number of involved skeletal
segments, 1st mo weekly, every 2 wk
thereafter
Cheng, 2011 Phase I, single arm,
centers unknown,
time period
unknown
64/8 RE-188–HEDP,
20 to 50 MBq/kg
None 8 wk Toxicity, pain
reduction
None VAS weekly, also pain diary
aDoctor or family could refuse lower dose of Sm-153–EDTMP.
bTreatment unblinded for patients who did not respond by wk 4, those who had received placebo could be given Sm-153–EDTMP, 1.0 mCi/kg, in an open manner.
NSCLC, non–small cell lung cancer; QoL: quality of life; EDTMP, ethylenediaminetetra(methylene phosphonate); HEDP, 1-hydroxy ethylidene-1,1-diphosphonic acid; IV, intravenously; VAS,
Visual Analogue Scale; KPS, Karnofsky performance score; ECOG, Eastern Cooperative Oncology Group; AUC, area under the curve; SEP, sum of effect product; PGA: Physician Global
Assessment; CR, complete response; NR, no response; PR, partial response.
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162 Hendriks et al Journal of Thoracic Oncology Vol. 11 No. 2each study. Because only one study examining denosu-
mab with zoledronic acid as an active comparator was
found, it was grouped within the table and results
related to bisphosphonates.Bisphosphonates and Denosumab
Thirteen studies (two of which were abstracts only)
were found, with one study concerning both denosumab
and bisphosphonates.24–37 The update of the study of
Rosen et al. was not counted as an extra study; rather, its
results were documented and combined with the orig-
inal 2003 study.34,35
Included Patients. In seven studies, all the included
patients had NSCLC.24,25,27,29,30,36,37 In the remaining
six, patients with NSCLC comprised a subgroup (34%–
86%).26,28,31–35
Bisphosphonates Evaluated. All the studies except two
evaluated the effect of zoledronic acid.24–29,31,32,34–37
The remaining two studies evaluated clodronate and
ibandronate, respectively.30,33 In all the studies patients
also received systemic anticancer treatment.
Study Designs Used. Only two phase III studies
including a subgroup of patients with NSCLC (44.0%–
48.9%) were found; pain was evaluated as a secondary
end point or in an ad hoc analysis, and QoL was not
evaluated. Subgroup analyses for patients with NSCLC
were not performed; SREs were the primary end
point.28,34,35 Two studies had a retrospective design.25,32
Nine studies were either phase II studies or their design
was not clear. Four of the nine studies were two-arm
studies,27,29,33,37 although only one of them was a ran-
domized double-blind study.33 One randomized study
did not clearly specify whether it was a blinded study.27
In another study the groups were unbalanced: one arm
consisted of patients with bone pain (they were treated
with zoledronic acid), and the other arm consisted of
patients without bone pain (they did not receive zole-
dronic acid).37 In the ﬁnal study patients who had not
consented to participate in it were used as the control
group.29
Methods of Pain Measurement. Measurements of pain
varied between studies and consisted, for example, of
the visual analogue scale (VAS),25,33,37 the Brief Pain
Inventory (BPI),26,28,32,34–36 analgesic consumption
diaries,24,26,28,30,31,33–35 or a six-point pain intensity
scale.27 Frequency of pain evaluation varied between
every 3 and every 6 weeks. Pain was evaluated in all the
studies, although in one study it was evaluated only as a
part of the Lung Cancer Symptom Scale (LCSS).29Methods of QoL Measurement
QoL was evaluated in only ﬁve studies. The evalua-
tion methods used were the Functional Assessment of
Cancer Therapy–G,26,34,35 the European Organisation for
Research and Treatment of Cancer Quality-of-Life
Questionnaire C30,25,32 and the LCSS.29 In one study
the short version of the BPI was used to measure extent
to which pain interfered with daily life, which served as a
surrogate for QoL.28
Radioisotopes
Twelve radioisotope studies were found. All were
prospective, although the phase of the study was not
always clearly documented.22,38–48
Included Patients. None of the studies included only
patients with NSCLC, although in two studies the other
patients included all had SCLC.43,48 In ﬁve other studies
the exact number of patients with NSCLC in the lung
cancer subgroup was not clear.38,41,44,46,47
Radioisotopes Evaluated and Study Design Used. In
ﬁve studies samarium was evaluated (two phase I or II
studies, one phase III study, and two single-arm studies
with the phase unknown); single doses varied between
3.7 MBq/kg and 111 MBq/kg and treatments were
repeated when necessary.38,40,44,46,47 Only one single-
arm study for strontium was found; it involved a single
dose of 150 MBq/kg (repeated when necessary).41 In the
remaining six studies rhenium (186Re or 188Re) was
evaluated. All the studies except one were single-arm
phase II studies, and the mean single doses varied
between 1158 MBq/kg and 1295 MBq/kg. Again, treat-
ment could be repeated when necessary.22,42,43,45,48
In the other study (phase I) escalating doses from 20
to 50 MBq/kg were used.39
Methods of Pain Measurement. For pain measure-
ment, the VAS,38–40,43 a composite pain score,41,44 a
score combining the effect on pain intensity and time
until a decrease in pain,47 and a three- or four-point
pain scale were used,45,48 as were analgesic con-
sumption scores.39–41,43 When mentioned, the fre-
quency of evaluations was mostly weekly for the ﬁrst
months with a lower frequency (once or twice a
month) thereafter.22,39,43,45,47,48 Responses were not
always clearly deﬁned, but in general, they consisted
of a decrease in pain score or analgesic consumption
score.
Methods of QoL Measurement. Only one study
included a surrogate outcome measure (sleep duration,
mobility, mood, and daily activities) for QoL.43
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Bisphosphonates and Denosumab: Effect on Pain
The results are summarized in Table 4. Time of onset
of pain reduction was provided in only two studies: after
six cycles (each cycle lasted 3 to 4 weeks) and after 1
month, respectively.26,27 In the two randomized studies
of zoledronic acid (one versus placebo, one versus
ibandronate), there were no signiﬁcant differences in
pain score between the groups.27,34,35 In one of these
studies, however, the BPI score for the subgroup of pa-
tients with pain at baseline decreased at 9 months
(signiﬁcance unknown), although no subgroup analysis
of the pain of patients with NSCLC was performed.34,35
In the other study (limited to patients with NSCLC),
there was a trend toward a faster decrease in pain in the
zoledronic acid group after 1 month (p ¼ 0.05) than in
the ibandronate group, although there was no signiﬁcant
difference in pain at 3 months (p ¼ 0.31). Of the patients
in the two studies, 61% and 56%, respectively, had a
decrease in pain score of two or more points at 3 months
(on a six-point pain intensity scale).27 In the one study in
which patients with NSCLC who refused to enter the
study served as a control group, the patients treated
with zoledronic acid manifested less need for radiation
and a trend toward less pain (p ¼ 0.08) compared with
those in the control group.29 No difference in pain effect
was found in an imbalanced study that included patients
with NSCLC with bone pain in one group and patients
with NSCLC without bone pain in another group.37 In all
the single-arm studies of zoledronic acid, a decrease in
pain score, analgesic use, or both was found for some of
the patients (decrease in pain score 38%–77%,
decreased or stable analgesic use 58%–75%), especially
in the case of those patients with moderate or severe
pain at baseline. Patients were also treated with
chemotherapy. In the three studies not limited to pa-
tients with NSCLC, no subgroup analysis was performed
for NSCLC.26,31,32 In the randomized study examining
clodronate versus placebo, a signiﬁcantly lower increase
in analgesic use was found (18% versus 54%) for the
clodronate group, although the pain scores were not
signiﬁcantly different.33 In the single-arm study of
ibandronate (plus chemotherapy), 16% of patients had a
reduced need for analgesics and 59% a stable need. Pain
scores were not provided.30 In the randomized study of
denosumab versus zoledronic acid, the patients who
were treated with denosumab and had no pain or mild
pain at baseline exhibited a signiﬁcantly longer time
before experiencing more than a four-point increase in
BPI score than did the patients treated with zoledronic
acid (p ¼ 0.05), and their analgesic use was lower. Also,
patients without severe pain at baseline took a signiﬁ-
cantly longer time to reach a two-point or greaterincrease in BPI score (p ¼ 0.016). Subgroup analysis for
NSCLC was not performed.28
Because of the different methods and time points
used for pain evaluation, it was not possible to perform a
meta-analysis. Of the 2606 patients included in the
studies, 1217 were diagnosed with NSCLC. When the
results are summarized for the studies that included
only patients with NSCLC or in which a subgroup anal-
ysis was performed for patients with NSCLC, a total of
489 patients with NSCLC were evaluated (seven studies,
four with one arm and three with two arms [one
unbalanced]).24,25,27,29,30,36,37 The results are summa-
rized for the patients for whom data were available. Of
those patients, 26% (range 16%–36%) had a decrease in
pain medication used, 25% had an increase in analgesic
consumption, and the others had a stable need for such
medications (two studies, N ¼ 85).24,30 A mean of 66.7%
of patients (range 60%–77%) reported a decrease in
pain score (three studies with a total of 225 patients);
however, only in one study (N ¼ 35) was this decrease
further speciﬁed: the mean BPI score decreased 2.6
points from baseline to a mean score of 1.0 after 6
weeks.25,27,36 In one other study (N ¼ 35), the LCSS pain
score remained stable in the zoledronic acid group but
decreased by 20 points in the no–zoledronic acid group
(a higher score indicates less pain).29 In this study, pa-
tients treated with zoledronic acid received
less radiotherapy than did patients not treated with
zoledronic acid (16.7% versus 70.6%).29
Bisphosphonates and Denosumab: Effect on QoL
In two of the ﬁve studies evaluating QoL, a signiﬁcant
improvement in QoL was found. They were single-arm
studies, and in the study not limited to patients with
NSCLC, subgroup analysis was not performed.25,26 In the
study of denosumab versus zoledronic acid, the time
until an increase in the extent to which pain interfered
with daily life (used as surrogate for QoL) was longer in
patients treated with denosumab and with no pain or
mild pain interference at baseline. Subgroup analysis for
NSCLC was not performed.28
Radioisotopes: Effect on Pain
The results are summarized in Table 5. In the case of
samarium, 60% to 95% of patients experienced a
decrease in pain. When mentioned, onset of pain reduc-
tion occurred within approximately 1 week.38,40,44,46,47
However, only two of ﬁve studies reported on NSCLC
separately.40,47 In one study, only 20% of patients with
NSCLC responded (40% had no response and the
remaining 40% were not evaluable owing mainly to
early death).40 In the other study, however, no differences
in pain relief between subgroups were found, and the
Table 4. Outcomes of the Trials Examining Bisphosphonates and Denosumab
Trial, y R or P
Total
Patients/
Patients
with
NSCLC
Arms Speciﬁed
when Necessary
Pain/QoL
Outcome for
Total Group
or NSCLC
Subgroup Also? Outcome: Pain Outcome: QoL
Bisphosphonates
Piga, 1998 P 66/17 A: clodronate
B: placebo
No Overall
- Response rate not mentioned, no signiﬁcant differences in pain
score (although 1.1-point decrease in arm A and 1.3-point
increase in arm B, p ¼ 0.42)
- Onset/duration of pain reduction not mentioned
- Analgesics: increase in 18.5% of patients in arm A vs. in
54.4% in arm B, p ¼ 0.04
Not provided
Rosen, 2003,
update
follow-up:
Rosen, 2004
P 773/378 A: CT with ZOL
B: CT with placebo
No Overall
- Response rate not mentioned, slight increase in mean BPI
score from baseline to 9 mo for all groups, mean composite
score decreased for arm A patients with pain at baseline
- Onset/duration of pain reduction not mentioned
- Analgesics: for both groups increase in analgesic use
For both groups decrease in
functional capacity
Kiaga, 2006 P 32/32 CTwith IBA Total group
(patients with
NSCLC only)
Overall (patients with NSCLC)
- Response rate not mentioned
- Onset/duration of pain reduction not mentioned
- Analgesics: 16% of patients had reduced need for analgesics,
59% had stable need, and 25% had increased need
Not provided
Facchini,
2007
P 60/28 CTwith ZOL Total group
(16 patients
excluded for not
completing
study)
Overall
- Response: 77.2% of patients had moderate or greater pain
at baseline vs. 29.5% after 12 cycles (48 wk) (p < 0.001)
- Onset of pain reduction: after 6 cycles
- Duration of pain reduction: at least until wk 48 (end of study)
- Analgesics: maximum decrease after 3 cycles (p ¼ 0.006), then
steady state
Signiﬁcant improvement in QoL
(p ¼ 0.02)
Kotteas,
2008
P 86/74 CTwith ZOL Total group Overall
- Response rate, see analgesics
- Onset/duration of pain reduction not mentioned
- Analgesics: after 3 cycles (86 patients): 8.1% of patients had
reduced need, 57% had stable need, and 34.8% had increased
need; after 6 cycles (52 patients): 5.8%, 59.6%, and 34.6%,
respectively
Not provided
Longo,
abstract
only, 2008
R? 24/18
(others
SCLC)
CT with ZOL Total group Overall (patients with lung cancer)
- Response rate not mentioned; severe pain at baseline:
“remarkable decrease”; low-grade pain at baseline:
“greater ﬂare-up after ﬁrst dose of ZOL”
- No mention of onset/duration of pain or analgesics
“Remarkable worsening of several
functions and a stability of the
emotional one.”
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Table 4. Continued
Trial, y R or P
Total
Patients/
Patients
with
NSCLC
Arms Speciﬁed
when Necessary
Pain/QoL
Outcome for
Total Group
or NSCLC
Subgroup Also? Outcome: Pain Outcome: QoL
Zarogoulidis,
2009
P 144/144 A: bone pain,
CT with ZOL
B: bone pain,
CT only
Total group
(patients with
NSCLC only)
Overall (patients with NSCLC)
- Response: “no statistically signiﬁcant difference between the
2 patient groups regarding to the pain effect of ZOL compared
with at baseline (p > 0.05)” (time point for comparison of both
groups not mentioned)
- Onset/duration of pain reduction not provided
- Analgesics not provided
Not provided
Francini, 2010 P 55/55 A: CT with ZOL
B: CT with IBA
Total group
(patients with
NSCLC only)
Overall (patients with NSCLC)
- Response rate not mentioned
- Onset of pain reduction: at 1 mo trend to more rapid decrease
in pain in ZOL group (p ¼ 0.05)
- Duration of pain reduction: maximum pain relief at 3 mo: no
difference (p ¼ 0.31), patients with 2-point increase in pain
relief at 3 mo: 61% vs. 56%
- Analgesics: difference between groups not mentioned
Not provided
Ishiwata, 2011 P 35/35 A: CT with ZOL
B: CT
Total group
(patients with
NSCLC only)
Overall (patients with NSCLC)
- Response rate not mentioned
- Onset of pain relief: at 8 wk pain relief higher in group A
(p ¼ 0.03), at 16 wk trend to more pain relief in group A (p ¼ 0.08)
- Duration of pain relief not mentioned
- Analgesics not mentioned
- Radiation treatment at 3 mo: group A 16.7% of patients, group B
70.6% (p ¼ 0.001)
“No signiﬁcant difference”
Del Signore,
2012 (abstract
only)
R 135/135 CTwith ZOL Total group
(patients with
NSCLC only)
Overall (patients with NSCLC)
- Response: “bone pain in 80% of patients, in 60% decrease in
pain during treatment”
- Onset/duration of pain relief not mentioned
- Analgesics not mentioned
“improved QoL,” not speciﬁed
Yoh, 2012 P 35/35 CTwith ZOL Total group
(patients with
NSCLC only)
Overall (patients with NSCLC)
- Response 27 patients (77%) improved in BPI, mean score at
baseline 2.6, after 6 wk 1.0 (p < 0.0001)
- Onset/duration of pain relief not mentioned (only measurements
at baseline and 6 wk)
- Analgesics not mentioned
Not provided
Davidov, 2013 P 53/53 CTwith ZOL Total group
(patients with
NSCLC only)
Overall (patients with NSCLC)
- Response rate not mentioned
- Onset/duration of pain relief not mentioned
- Analgesics: 35.9% of patients had reduced need, 39.6% had
stable need, 24.5% had increased need after 6 cycles
- Additional radiation therapy: 6 patients (11.3%) for pain
Not provided
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166 Hendriks et al Journal of Thoracic Oncology Vol. 11 No. 2response rates were greater than 80%.47 When men-
tioned, mean duration of pain relief was between 1 and
3.8 months.
In the subgroup of patients with lung cancer who
were treated with strontium (n ¼ 24), all patients
experienced pain relief and a reduction in analgesic use.
Onset of pain reduction was not mentioned; the mean
duration was 3.3 months.41
Between 62% and 84% of patients with NSCLC or
lung cancer who were treated with rhenium had a
decrease in pain, and approximately 35% had a complete
response.22,39,45,48 One of the studies did not mention
the response percentage; the decrease in VAS score was
3.5 points. Time until onset of pain relief was not
mentioned for the lung cancer subgroup; for the total
group, it was within 1 week.43 One study that included
ﬁve patients with lung cancer reported results conﬂict-
ing with the aforementioned results. In it, improvement
in performance score was used as a surrogate for pain.
Only two patients (40%) responded, one with a 75%
improvement in performance score and one with a 20%
improvement.42 Only one study of rhenium mentioned
the duration of the response of patients with NSCLC
(median 10 weeks).22 In the other studies, the duration
of the response of the total group ranged from 1 to
3 months.39,43,45
In the aforementioned studies, a total of 713 patients
were treated with radioisotopes, NSCLC was diagnosed
in 199 (in 72 of 199 cases the diagnosis not speciﬁed
further than “lung cancer”). The 10 studies that were
limited to patients with NSCLC or in which a subgroup
analysis for patients with NSCLC was performed
included a total of 170 patients with NSCLC (all
except two were single-arm studies).22,39-43,45-48 Seven
studies (N ¼ 117) mentioned a response percentage:
a mean of 65.7% of patients responded (range 20%–
100%).12,22,39-41,45,48 Only two studies (N ¼ 48)
mentioned duration of response (mean 2.9 months).22,41
Two studies (N ¼ 56) reported on analgesic intake; a
mean of 79.9% of patients had a decrease (range 59.7%–
100%).41,48 Pain scores were reported in two studies
(N ¼ 12); the mean decrease was 2.2 points (3.75 points
when only the highest dose of samarium was taken into
account).43,46
Radioisotopes: Effect on QoL
In the only study in which QoL was speciﬁed in the
Methods section (daily functioning served as a surro-
gate), 91% of patients improved. A subgroup analysis for
NSCLC was not performed.43 Although one study did not
include a description of the method for evaluation of
QoL, its authors stated in their results that “responding
patients had an improvement in QoL.”47 The other
studies did not report on QoL.
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In this systematic review, no randomized studies
evaluating bisphosphonates or denosumab in NSCLC
with pain, QoL, or both as a primary end point were
found; moreover, most studies did not include mea-
surements of QoL. Therefore, no high-level evidence that
one of these agents reduces or prevents pain or improves
QoL was found. In one randomized study (zoledronic
acid versus ibandronate) that included only patients with
NSCLC, there was a trend toward a more rapid decrease
in pain in the zoledronic acid group; however, at
3 months this difference had disappeared.27 In the
other randomized studies, no NSCLC subgroup analyses
with respect to pain and QoL were performed.28,33-35 In
the single-arm studies of zoledronic acid, a decrease in
pain and analgesic consumption was found for some of
the patients (38%–77%).26,30,31,36 Patients were also
treated with chemotherapy, and the effects of the sepa-
rate treatments are not clear. In the study of denosumab
versus zoledronic acid, which did not include a subgroup
analysis for NSCLC, it was found that in particular,
patients with no pain or mild baseline pain have a longer
time until an increase in pain when treated with deno-
sumab than when treated with zoledronic acid.28
Most studies did not include QoL measurements, and
an improvement in Qol was found in only two of the ﬁve
studies that did.25,26
The effect of bone-targeted agents seems to be tumor
dependent; however, no phase III trials that included
patients with NSCLC only, regardless of the primary end
point, were found.
In most studies, the primary end point was preven-
tion or delay of onset of SREs. Although pain and QoL are
important issues for patients, they are not included in
the deﬁnition of SRE. Furthermore, pain treatment can
be subdivided into semidirect pain relief after adminis-
tration of a drug (e.g., a treatment effect within 1 week)
and long-term prevention of pain or prevention of an
increase in pain. Direct effects in the form of pain
reduction were not mentioned; pain reduction or pre-
vention was not uniformly reported (the time points
evaluated varied from 1 to 9 months). Palliative radio-
therapy can be used as an indirect measure of bone pain,
but the decision regarding when to use radiotherapy is a
subjective one and also dependent on local policies.
Moreover, radiotherapy can be used only for one or a
few painful bone metastases. Furthermore, palliative
radiotherapy has minimal toxicity; only a limited number
of visits to the clinic are needed, and radiotherapy is
often highly effective in controlling bone pain.49
It seems that radioisotopes (samarium, strontium, and
rhenium) have a palliative effect on pain with a rapid
onset of action and duration of response of approximately1 to 3months. However, the data onNSCLC are limited and
consist of subgroup analysis of mostly phase I and II
studies. There was only one randomized, placebo-
controlled phase III trial, and lung cancer was diagnosed
in only six of its 118 patients. The other radioisotope
studies did not include aplacebo arm, and it is likely that at
least part of the observed pain relief was due to the pla-
cebo effect. Because radioisotope treatment can be
repeated, the relatively short duration of response does
not seem to be problematic. However, radioisotopes can
cause bone marrow suppression, and combining them
with palliative systemic therapy is not advisable. There-
fore, radioisotopes seem to be an option only when pa-
tients do not receive active anticancer therapy and have
bone pain that is not eligible for palliative radiotherapy.
Most of the current NSCLC guidelines include some
recommendations regarding bone-targeted agents and
bonemetastases. Zoledronic acid is the only bisphosphate
with regulatory approval for the prevention of SREs. The
National Comprehensive Cancer Network guideline
(2015), National Institute for Health and Care Excellence
lung cancer guideline (2011), and European Society for
Medical Oncology guideline for NSCLC (2014) all recom-
mend that zoledronic acid or denosumab be used in pa-
tients with bonemetastases. Whenmentioned, such use is
to prevent SREs.4,6,7 In the European Society for Medical
Oncology clinical practice guideline on bone health in
patients with cancer (2014), this advice is further reﬁned.
Zoledronic acid or denosumab are advised in selected
patients with lung cancer who are at high risk for occur-
rence of SREs and have a life expectancy of more than 3
months.5 Pain reduction or prevention of an increase in
pain is not mentioned. Neither do the aforementioned
guidelines discuss the potential use of radioisotopes.
In daily practice, bone-targeted agents are prescribed to
reduce time until occurrence of a SRE, reduce number of
SREs, and indirectly reduce or prevent pain and a decrease
in QoL. Pain relief from bisphosphonates is suggested in a
fairly recent (2009) expert panel consensus.50 The panel
refers to the randomized study of Rosen et al.,35which does
not specify pain relief for the NSCLC subgroup, however.
As is clear from our systematic review, there is no
high-level evidence that zoledronic acid or denosumab
have an effect on pain or QoL in patients with NSCLC. Even
when present, onset of pain relief is unclear. In the recent
literature, moreover, whether use of SREs is the most
clinically relevant end point for patients is also ques-
tioned. It is suggested that a more holistic approach and
more patient-centered outcomes—symptomatic skeletal
events (SSEs)—be used instead of SREs (SSEs are SREs,
but without asymptomatic pathological fractures).10 So,
to decide whether bone-targeted agents are useful, one
should take into account not just patient-centered
Table 5. Outcomes of Tials Examining Radioisotopes
Trial, y R or P
All Patients/
Patients with
NSCLC
Arms Speciﬁed
when Necessary
Pain/QoL
Outcome for
Total Group or
Also NSCLC
Subgroup? Outcome: Pain Outcome: QoL
Farhanghi, 1992 P 22/5 Sm-153–EDTMP Also NSCLC
subgroup (only
for response)
Overall
- Response rate: 65.4%
- Onset of pain reduction: not mentioned
- Duration: mean 3.8 mo
- Analgesics: 18.2% discontinued analgesics
NSCLC
- Response rate: 20% (40% no response, 40% not evaluable)
Not provided
Alberts, 1997 P 28/9 (“lung
cancer”)
Sm-153–EDTMP No Overall
- Response rate: 78%–95% of patients had improvement in
pain
- VAS: median 4-point decrease
- Onset of pain reduction: usually at 48 h
- Duration: median 31–56 d
Not provided
Kasalicky, 1998 P 118/31 (“lung
cancer”)
89SRCl Also “lung
cancer”
subgroup
Overall
- Response rate: 96.6%, (near) complete 78.8%
- Duration: mean 3.3 mo
- Onset of pain reduction: not mentioned
- Analgesics: decreased in 94.1% of patients, 2.6%
discontinued analgesics
Lung cancer
- Response rate: 100%, (near) complete 90%
- Duration: mean 3.3 mo
- Onset of pain reduction: not mentioned
- Analgesics: 100% of patients had a decrease in use
Overall
Improvement in general
condition 96.6%
Lung cancer
Improvement in general
condition 100%
Seraﬁni, 1998 P 118/6 A: Sm-153–EDTMP,
18.5 MBq/kg
B: Sm-153–EDTMP,
37 MBq/kg
C: placebo
Also NSCLC
subgroup (only
for AUPC-VAS)
Overall
- Response at wk 4: A, 65%; B, 62%; C, 40%
- Duration: not speciﬁcally mentioned, lasting until wk 16 for
most patients in Group B, almost none in Group C
- Onset of pain reduction: within 1 wk
- Analgesics use at wk 4: ±35% decrease in group A, ±20%
decrease in group B, ±20% increase in group C
Lung cancer
- In arm A, þ1 on AUPC-VAS at 4 wk; in arm B and C,
respectively, –4 and þ 4
Not provided
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Table 5. Continued
Trial, y R or P
All Patients/
Patients with
NSCLC
Arms Speciﬁed
when Necessary
Pain/QoL
Outcome for
Total Group or
Also NSCLC
Subgroup? Outcome: Pain Outcome: QoL
Tian, 1999 P 105/41 (“lung
cancer”)
A: Sm-153–EDTMP,
37 MBq/kg
B: Sm-153–EDTMP,
18.5 MBq/kg
Mentioned only
that subgroup
analysis per
primary tumor
was performed
Overall:
- Response rate: arm A 82.9%, arm B 85.7%
- Duration: mean 8.6 wk in both arms
- Onset of pain reduction: mean 8.78 d
- SEP: group A 22.3, group B 20.1
- Analgesics: dose reduction/cessation in 55.7% of patients in
arm A and 68.6% in arm B
NSCLC
- “No differences for subgroup analysis”
- SEP: 17 for both arms
Not provided in detail:
“QoL increased in
responding patients”
Küçük, 2000 P 31/5 Re-186–HEDP Also NSCLC
subgroup
Overall:
- Response rate: 67.5%
- Duration: mean 8.1 wk
- Onset of pain reduction: not mentioned
NSCLC
- Response rate: 20% (1 patient) major response, 20%
(1 patient) minor response
- Duration and onset: not provided
Not provided
Li, 2001 P 61/26 Re-188 HEDP Also NSCLC
subgroup (only
for response)
Overall:
- Response: 36% complete response, 44% signiﬁcant response
- Duration: 1–3 mo
- Onset of pain reduction within 1 wk for 80%
- Number of treatments for pain: 1 (62%), 2 (16%), others 3–6
NSCLC:
- Response rate: 77%
- Duration/onset of pain relief: not mentioned
Not provided
Li, 2002 P 66/20 (“lung
cancer”)
Sm-153–EDTMP No Overall
- Composite score: CR 25.7%, PR 36.4%, NE 37.9%
- Duration/onset of pain relief: not mentioned
Not provided
Zhang, 2003 P 30/25 (others
SCLC)
Re-188–HEDP Also NSCLC
subgroup (only
for pain relief,
not for analgesic
intake)
Overall:
- Response rate: 80% of patients had pain relief, 33% had
complete response
NSCLC:
- Response rate: 84% pain relief, 36% complete response
- Onset of pain reduction: within 1 wk
- Analgesics: analgesic intake discontinued by 46.7% of
patients, decreased by 13%, remained stable by 16.7%, and
increased by 23.3%
Not provided
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Table 5. Continued
Trial, y R or P
All Patients/
Patients with
NSCLC
Arms Speciﬁed
when Necessary
Pain/QoL
Outcome for
Total Group or
Also NSCLC
Subgroup? Outcome: Pain Outcome: QoL
Leondi, 2004 P 24/6 (others
SCLC)
Re-186–HEDP Also NSCLC
subgroup (only
for VAS)
Overall:
- Response rate: 95.8% pain relief, 37.5% complete
- VAS: Mean difference before and after treatment: –3.7.
clinically signiﬁcant (–3 VAS)
- Duration mean 1.5 mo
- Onset of pain relief: within 1 wk in 62%,
- Analgesics: 77% of patients reduced opioid intake
NSCLC:
- VAS: mean difference before and after treatment –3.5
- Duration and onset of pain relief: not mentioned
91% of patients had
improvement in sleep,
mobility, mood,
communication ability
Minutoli, 2006 P 41/17 Re-186–HEDP Also NSCLC
subgroup
Overall
- Response rate: 85.4% (49% complete)
- Duration: median 10 wk
- Onset of pain reduction: within 1 or 2 wk
NSCLC
- Response rate: 76.5% (35% complete)
- Duration: median 10 wk
- Onset of pain relief: not mentioned
Not provided
Cheng, 2011 P 64/8 Re-188–HEDP Also NSCLC
subgroup (only
for pain relief)
Overall
- Response rate: 73.3% (10% complete)
- VAS: after 4 wk –3.22 from nadir, after 8 wk þ1.78 from
nadir
- Duration of pain relief: mean 6.9 wk
- Onset of pain reduction: within 1 wk
NSCLC
- Response rate: 62.5%
- Onset/duration of pain relief: not mentioned
Not provided
R, retrospective; P, prospective; NSCLC, non–small cell lung cancer; QoL, quality of life; EDTMP, ethylenediaminetetra(methylene phosphonate); HEDP, 1-hydroxy ethylidene-
1,1-diphosphonic acid; AUPC-VAS, area under the pain curve–visual analogue scale; SEP, sum of effect product; CR, complete response; PR, partial response; NE, not evaluable.
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(SRE or SSE), and toxicities.
In conclusion, the evidence that bisphosphonates or
denosumab reduce or prevent pain in patients with
NSCLC with bone metastases or that they have an in-
ﬂuence on QoL is very scant. Radioisotopes seem to have
a palliative effect on pain with a rapid onset of action,
although there is no high-level evidence of such an effect.
Our opinion is that there is room to evaluate the
clinical beneﬁt of bisphosphonates or denosumab in
patients with NSCLC with bone metastases. The primary
end point should consist of a patient-relevant outcome—
for example, a composite end point of frequent mea-
surements of pain and QoL combined with determina-
tion of the incidence of clinically relevant fractures and
spinal cord compression. Such a study should include
patients with NSCLC only, and it should be a randomized,
double-blind study to exclude the effects of palliative
systemic therapies (chemotherapy as well as targeted
therapies) on these outcomes, especially the “weak” end
points such as pain and QoL. Pain relief should be
measured by standardized, reliable questionnaires (e.g.,
the Bone Metastases Quality-of-Life Questionnaire and
the Bone-Metastases-22 module of the European Orga-
nisation for Research and Treatment of Cancer Quality-
of-Life Questionnaire C30).51,52Appendix. The Search StrategyPICO Components Search Terms
Patient NSCLC OR
Non–small cell lung cancer
AND
Bone metastases OR
Bone neoplasm
Intervention AND Bisphosphonates OR
Zoledronic acid
Radionuclide
Strontium
Samarium
Rhenium
Radioisotopes
Radioactive-labeled
bisphosphonates
Bone-targeted agents
Denosumab
Rank ligand
Comparator Not speciﬁed in search strategy to
allow inclusion of single-arm studies
Outcome Not speciﬁed in search strategy to
allow inclusion of studies in which
pain was not a primary outcome
PICO, patient, intervention, comparator, outcomes; NSCLC,
non-small cell lung cancer.References
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